| 5.59 0.01 (0.18%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.52 | 1-year : | 7.62 |
| Resists | First : | 5.59 | Second : | 6.52 |
| Pivot price | 5.59 | |||
| Supports | First : | 5.58 | Second : | 5.57 |
| MAs | MA(5) : | 5.59 | MA(20) : | 5.59 |
| MA(100) : | 5.59 | MA(250) : | 4.81  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 100 | D(3) : | 100 |
| RSI | RSI(14): 78.6 | |||
| 52-week | High : | 5.59 | Low : | 3.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATRS ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 5.6 - 5.62 | 5.62 - 5.65 |
| Low: | 5.51 - 5.55 | 5.55 - 5.57 |
| Close: | 5.54 - 5.59 | 5.59 - 5.63 |
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Tue, 24 May 2022
Halozyme Completes Antares Pharma Acquisition - PR Newswire
Wed, 13 Apr 2022
Halozyme Therapeutics Agrees to Buy Antares Pharma - The Wall Street Journal
Wed, 13 Apr 2022
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity - Yahoo Finance
Wed, 13 Apr 2022
Halozyme acquires Antares Pharma for $960M to create drug delivery company - Drug Delivery Business News
Wed, 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader - PR Newswire
Wed, 13 Apr 2022
Antares Pharma Stock Soars After $960 Million Halozyme Buyout - Barron's
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 171 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 62.8 (%) |
| Shares Short | 4,780 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | -0.03 |
| EPS Est This Year | -0.11 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.02 |
| Profit Margin | 21.8 % |
| Operating Margin | 10.4 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 26.6 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 0.67 |
| Sales Per Share | 1.07 |
| EBITDA (p.s.) | 0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 30 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | 24.3 |
| PEG Ratio | 0.8 |
| Price to Book value | 5.42 |
| Price to Sales | 5.2 |
| Price to Cash Flow | 32.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|